Drug Delivery

Study supports electroporation-mediated DNA delivery without anesthesia

Published in Gene Therapy Weekly, September 16th, 2004

Genetronics Biomedical Corp. (AMEX), a late-stage developer of cancer and other therapies using electroporation-enabled delivery of drugs, DNA vaccines, and genes, announced that a study assessing the clinical utility of an electroporation-mediated method for delivering DNA in humans without anesthesia showed this method was safe and tolerable.

The results of this Investigational Review board (IRB)-approved pilot study, which measured pain response in healthy volunteers using an electrical pulse suitable for DNA delivery using Genetronics' MedPulser DNA Delivery System, support electroporation as a potentially attractive DNA delivery method for potential use in humans...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-09-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry